Interviews

Subcutaneous checkpoint inhibitors drove up volume and forced staffing changes, according to Angie Maynard, PharmD, MS, BCOP, and bispecifics will bring another shift.

Deepak Bhatt, MD, MPH, MBA, discusses how new evidence, prevention definitions, and imaging advances are reshaping how PCSK9 and SGLT2 inhibitors are used.

Deepak Bhatt, MD, MPH, MBA, discusses hot new topics reshaping care for diabetes, obesity, and cardiovascular disease.

Stefanie Houseknecht, PharmD, explains how oncology pharmacists support biomarker testing, targeted therapy selection, and patient education in lung cancer care.

Robert Kratzke, MD, discusses how biomarker testing mandates and faster sequencing can improve access to precision lung cancer care.

Jennifer Sheng, MD, discusses how multidisciplinary collaboration, tumor boards, and coordinated care improve breast cancer treatment and survivorship.

Stefanie Houseknecht, PharmD, discusses patient education, financial barriers, and pharmacy's expanding role in precision lung cancer care.

Jennifer Sheng, MD, discusses how consistent follow-up, patient education, and lifestyle interventions improve breast cancer survivorship care.

Expanding on IVBM insights, Robert Kratzke, MD, discusses biomarkers, NGS panels, and treatment options for early-stage NSCLC without actionable alterations.

Jody Agena, PharmD, discusses staffing, communication, and operational readiness for implementing complex oncology therapies.

Minhee Kang, PharmD, explains how oncology pharmacists translate clinical research into safe, coordinated cancer care.

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, and care delivery.

Mohit Narang, MD, discusses how community oncology practices can expand access to CAR T and bispecific therapies through better infrastructure and collaboration.

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps when testing is negative for NSCLC.

Shared decision-making and quality of life are increasingly shaping metastatic breast cancer care amid persistent social barriers, notes Hayley Knollman, MD.

At the IVBM Charlotte event, Seungjean Chai, MD, emphasized that patient-centered design, guidelines, and subspecialty expertise are essential to high-value oncology care.

Kaitlyn Schomberg, PharmD, discusses BiTE therapy adoption, toxicity management, and care coordination in community oncology settings.

CAR-T and bispecifics in multiple myeloma are reshaping sequencing, enabling earlier use, but access and standardization challenges remain, per Sylvester Homsy, MD.

Parth Desai, MBBS, MD, discusses how clinicians balance liquid biopsy, tissue testing, and fast-start chemo to personalize non–small cell lung cancer treatment.

Clinical trials are evolving toward decentralized, patient-centered models, but enrollment challenges, outdated protocols, and infrastructure gaps persist.

New myeloma therapies—CAR T, bispecific antibodies, and oral CELMoDs—expand options, protect QOL, and raise hopes of cure, notes Asya Nina Varshavsky-Yanovsky, MD, PhD.

Hayley Knollman, MD, explains how ctDNA and genomic testing impact ER-positive metastatic breast cancer care, guiding sequencing decisions amid evolving HER2 categories.

Oral semaglutide hasn't shifted prescribing as expected. Shawn Davis, MD, discusses what access and policy changes are needed to close the coverage gap.

Amy Leader, DrPH, MPH, explains that trust is key to clinical trial enrollment at an Institute for Value-Based Medicine event in Philadelphia.

Equity gaps in lung cancer molecular testing persist; reflex testing and nurse navigation speed care, while coverage and access barriers stall outcomes

Reflex molecular testing and nurse navigation cut delays in lung cancer care, helping more patients get targeted results before first-line therapy, says Christopher D'Avella, MD.

With obesity costing $1.4 trillion annually, Shawn Davis, MD, argues the return on treatment investment is clear if we build systems to measure it.

Learn how CRS and ICANS present in patients undergoing immunotherapy and what clinicians should know about recognizing and managing these toxicities.